Insulin lispro - Sanofi

Drug Profile

Insulin lispro - Sanofi

Alternative Names: Insulin lispro Biosimilar - Sanofi; Insulin lispro Sanofi; SAR-342434

Latest Information Update: 23 May 2017

Price : $50

At a glance

  • Originator Sanofi
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 19 May 2017 CHMP recommends approval of Insulin lispro Sanofi® for Type-1 and Type-2 diabetes mellitus in the EU
  • 01 Sep 2016 Preregistration for Type-1 and Type-2 diabetes mellitus in European Union (SC) (Sanofi Quarterly report, October 2016)
  • 01 Jul 2016 Sanofi completes a phase III trial in Type-1 diabetes mellitus in USA, France, Germany, Hungary, Japan, Poland, Russia and Spain (NCT02273180)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top